Healio Community Case in DR/DME
Second-generation anti-vascular endothelial growth factor (VEGF) therapies provide patients with diabetic macular edema (DME) and diabetic retinopathy (DR) the opportunity for improved visual and anatomical outcomes with less-frequent dosing. However, managing patients with DME/DR can be complex, requiring collaborative-care approaches to offer personalized treatment options and address care disparities. In this CE activity, Drs. Christina Weng and Dennis Marcus discuss collaborative care approaches and individualized management options for a community-based DME patient case, offering clinical insights for the optimal incorporation of durable anti-VEGF therapeutic options into management protocols through analysis of the latest clinical evidence and patient characteristics and preferences.
Cost: Free
View Offer chevron_rightDetails
Second-generation anti-vascular endothelial growth factor (VEGF) therapies provide patients with diabetic macular edema (DME) and diabetic retinopathy (DR) the opportunity for improved visual and anatomical outcomes with less-frequent dosing. However, managing patients with DME/DR can be complex, requiring collaborative-care approaches to offer personalized treatment options and address care disparities. In this CE activity, Drs. Christina Weng and Dennis Marcus discuss collaborative care approaches and individualized management options for a community-based DME patient case, offering clinical insights for the optimal incorporation of durable anti-VEGF therapeutic options into management protocols through analysis of the latest clinical evidence and patient characteristics and preferences.
Topics Covered
DR/DME
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Individualize the use of durable anti-VEGF options based on the latest evidence, patient characteristics, and preferences for patients with DR/DME.
- Explore collaborative care approaches to address disparities in care surrounding the use of anti-VEGF treatments for patients with DR/DME.
Target Audience
The intended audience for this activity is US-based ophthalmologists and retina specialists involved in the management of patients with or at risk for retinal diseases.
Additional credit info
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.